Novel Target and Lead Compound to Reverse TBI-Induced Alzheimer's-Related Dementia
Abstract
It is estimated that >1.4 million Americans each year suffer a traumatic brain injury (TBI), defined as a blunt or penetrating injury to the head that alters brain function. Importantly, TBI is also a major health issue in the U.S. military, with estimates of TBI prevalence as high as 23 percent of returning service members (including both moderate/severe and mild concussive TBI). Mild (concussive) and moderate/severe TBI have both been linked to immediate and delayed development of long-term disabilities; predominantly reduced working memory, difficulty learning new information, execute function and reasoning. Interestingly, a similar array of cognitive deficits are observed in patients with Alzheimer's disease (AD) and AD related dementias (ADRD). Relevant to the current Program Announcement, there is an emerging consensus that traumatic brain injury (TBI) is associated with increased risk of future AD and ADRD and military personnel are increasingly living with TBI and associated risk of cognitive decline. Thus, it is critical to improve our understanding of the etiology of TBI-induced dementia and cognitive dysfunction with the goal of identifying new therapeutic targets to improve quality of life for the thousands to millions of military and civilian individuals living with TBI.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2020
- Accession Number
- AD1128070
Entities
People
- Paco S Herson
Organizations
- University of Colorado Denver